DATASET 2026-08-0941 PROGRAMS INDEXEDTIRZEPATIDE ALL-IN $215–$597/MOEVERY FIGURE CAPTURE-DATED & SOURCE-LINKED
TopGLP1Providers.comverified price index
VERIFIED 2026-08-09
NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓

2026-08-10 · SEMAGLUTIDE · TopGLP1Providers Data Desk

Semaglutide with B12: additive, argument, or both?

Compounded "semaglutide with B12" is semaglutide plus cyanocobalamin in the same vial. It exists for three reasons: pharmacies market B12 as helping with fatigue and nausea (evidence: thin), it lets a compounder argue the product is not an exact copy of Wegovy (a legal theory under direct FDA pressure), and it differentiates a commodity. By late 2025, more than 80% of compounded GLP-1 prescriptions included added vitamins or amino acids. It does not reliably cost more — dose-flat programs like NexLife↗ ($165) and Mochi ($178) price with or without additives identically — so the additive is rarely a price question and always a scrutiny question.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On the claimed benefits: B12 deficiency does cause fatigue, and correcting a deficiency helps — but most people starting semaglutide are not deficient, and no controlled trial shows added B12 reduces GLP-1 nausea. The honest case for the combination is convenience for people who would inject B12 anyway. The honest case against is that every additive is one more variable in a product that already lacks FDA review: concentration accuracy, stability, and sterility all now depend on the compounder's competence for two ingredients instead of one. The FDA has separately warned against unstudied salt forms of both molecules, and a March 2026 safety finding on tirzepatide–B12 adducts showed the agency is now examining the additive strategy chemically, not just legally — a signal that reads across to semaglutide combinations.

The regulatory subtext is the real story. Once the semaglutide shortage ended in February 2025, plain compounded copies lost their legal basis, and "plus B12" became partly a compliance costume: if it is a different formulation, the argument goes, it is not an essential copy. The FDA's April 2026 posture — enforcement against copies, plus the proposal to strip these molecules from the 503B bulks list — treats that argument with visible skepticism when the addition serves no documented patient need. Practical takeaway: if a program offers B12 formulations, that is unremarkable; if a program's entire legal story is the B12, that is the tell. Ask the one question that collapses it: "What is the documented clinical reason my prescription cannot be met by the FDA-approved product?" A legitimate 503A pathway has an answer about you. A costume has an answer about the vial.

Not medical advice. B12 status, nausea management, and formulation choice are prescriber conversations.

The cheapest compounded tirzepatide online rigThe cheapest compounded semaglutide online, inCompounded tirzepatide vs ZepboundWhat a year of tirzepatide actually costs, proDose-flat vs dose-tiered pricing